Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Treatment-related adverse events in the nivolumab cohort
| TRAEs | Nivolumab cohort (N = 325) |
|---|---|
| Any grade, n (%) | 104 (32.0) |
| Grade 1 | 64 (19.7) |
| Grade 2 | 40 (12.3) |
| Grade 3-4 | 36 (11.1) |
| Grade 3-4 in first 12 months | 34 (10.5) |
| Leading to discontinuation of nivolumab | 29 (8.9) |
| Serious TRAEs | 36 (11.1) |
| Time to onset of first TRAE (all grades), median (range), months | 1.5 (0-28.1) |
| Time to onset of first TRAE (grade 3 or 4), median (range), months | 4.0 (0.2-15.9) |
TRAEs, treatment-related adverse events.
